Recommendations on clinical application of deutetrabenazine for treatment of tardive dyskinesia
10.3969/j.issn.1002-0152.2025.02.001
- VernacularTitle:氘丁苯那嗪治疗迟发性运动障碍临床应用指导建议
- Author:
Dengtang LIU
1
;
Tianmei SI
;
Li KUANG
;
Qiang WANG
;
Yingjun ZHENG
;
Manli HUANG
;
Kaida JIANG
Author Information
1. 上海交通大学医学院附属精神卫生中心(上海 200030)
- Publication Type:Journal Article
- Keywords:
Tardive dyskinesia;
Deutetrabenazine;
VMAT2 inhibitor;
Pharmacology;
Pharmacokinetic
- From:
Chinese Journal of Nervous and Mental Diseases
2025;51(2):65-71
- CountryChina
- Language:Chinese
-
Abstract:
Deutetrabenazine(DTBZ)is a selective oral small molecule inhibitor of vesicular monoamine transporter 2(VMAT2).Its pharmacological action works by inhibiting VMAT2,thereby reducing the release of presynaptic dopamine and alleviating tardive dyskinesia symptoms caused by long-term use of dopamine receptor antagonists.Compared with tetrabenazine,DTBZ has longer half-life,lower peak plasma concentration,and smaller plasma concentration fluctuations.Clinical studies demonstrate that DTBZ significantly improves abnormal involuntary movement in patients with tardive dyskinesia and has a favourable safety profile.Based on available clinical evidence and practical experience,this paper discuss the common questions about DTBZ including the suitable population,dose,duration of treatment,combination administration with antipsychotics,efficacy assessment and application in special populations.This article aimed to provide guidance and recommendations on clinical application of DTBZ for clinicians.
